During the past decade, Center for Cancer and Blood Disorders conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 69 clinical trials were completed, i.e. on average, 135.3% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 22 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Cancer and Blood Disorders" #1 sponsor was "SCRI Development Innovations, LLC" with 40 trials, followed by "Celgene" with 18 trials sponsored, "Telik" with 10 trials sponsored, "Amgen" with 5 trials sponsored and "Incyte Corporation" with 5 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Cancer and Blood Disorders" #1 collaborator was "Genentech, Inc." with 10 trials as a collaborator, "Bristol-Myers Squibb" with 8 trials as a collaborator, "Novartis" with 7 trials as a collaborator, "Bayer" with 6 trials as a collaborator and "Amgen" with 4 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Center for Cancer and Blood Disorders" are "Multiple Myeloma" (31 trials), "Breast Cancer" (12 trials), "Chronic Lymphocytic Leukemia" (8 trials), "Metastatic Breast Cancer" (8 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Center for Cancer and Blood Disorders" in a lesser frequency.

Most popular intervention types in "Center for Cancer and Blood Disorders" are "Drug" (164 trials), "Biological" (7 trials), "Other" (6 trials), "Radiation" (4 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (18 trials), "Placebo" (17 trials), "Bevacizumab" (13 trials), "Dexamethasone" (12 trials) and "Bortezomib" (11 trials). Other intervention names were less common.

The vast majority of trials in "Center for Cancer and Blood Disorders" are 150 trials for "All" genders, 18 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Center for Cancer and Blood Disorders". undefined are not yet recruiting, 15 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 110 completed trials in Center for Cancer and Blood Disorders, undefined suspended trials, and 30 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Cancer and Blood Disorders, 42 "Phase 1" clinical trials were conducted, 106 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".